ERYTHROMYCIN ETHYLSUCCINATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Erythromycin Ethylsuccinate, and when can generic versions of Erythromycin Ethylsuccinate launch?
Erythromycin Ethylsuccinate is a drug marketed by Amneal Pharms, Ani Pharms, Cadila Pharms Ltd, Endo Operations, Alpharma Us Pharms, Dista, Naska, Parke Davis, Pharmafair, Aurobindo Pharma Usa, Azurity, and Barr. and is included in fourteen NDAs.
The generic ingredient in ERYTHROMYCIN ETHYLSUCCINATE is erythromycin ethylsuccinate; sulfisoxazole acetyl. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin ethylsuccinate; sulfisoxazole acetyl profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ERYTHROMYCIN ETHYLSUCCINATE?
- What are the global sales for ERYTHROMYCIN ETHYLSUCCINATE?
- What is Average Wholesale Price for ERYTHROMYCIN ETHYLSUCCINATE?
Summary for ERYTHROMYCIN ETHYLSUCCINATE
| US Patents: | 0 |
| Applicants: | 12 |
| NDAs: | 14 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 48 |
| Clinical Trials: | 1 |
| Patent Applications: | 1,569 |
| What excipients (inactive ingredients) are in ERYTHROMYCIN ETHYLSUCCINATE? | ERYTHROMYCIN ETHYLSUCCINATE excipients list |
| DailyMed Link: | ERYTHROMYCIN ETHYLSUCCINATE at DailyMed |
Recent Clinical Trials for ERYTHROMYCIN ETHYLSUCCINATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Florida | Phase 2 |
| Metabolic Solutions Inc. | Phase 2 |
Pharmacology for ERYTHROMYCIN ETHYLSUCCINATE
| Drug Class | Macrolide Antimicrobial Macrolide |
| Physiological Effect | Decreased Sebaceous Gland Activity |
Medical Subject Heading (MeSH) Categories for ERYTHROMYCIN ETHYLSUCCINATE
Anatomical Therapeutic Chemical (ATC) Classes for ERYTHROMYCIN ETHYLSUCCINATE
US Patents and Regulatory Information for ERYTHROMYCIN ETHYLSUCCINATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal Pharms | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | GRANULE;ORAL | 211204-001 | Nov 1, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pharmafair | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | SUSPENSION;ORAL | 062558-001 | Mar 15, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cadila Pharms Ltd | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | GRANULE;ORAL | 216212-002 | Nov 21, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
